Axsome Therapeutics Inc. | Mid-cap | Healthcare
$122.52
3.21%
| Axsome Therapeutics Stock Comparison:
Axsome Therapeutics vs VertexAxsome Therapeutics vs AlnylamAxsome Therapeutics vs MadrigalAxsome Therapeutics vs Bio-TechneAxsome Therapeutics vs Corcept TherapeuticsAxsome Therapeutics vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 121.5M
Gross Profit 111.7M 91.94%
Operating Income -55.5M -45.67%
Net Income -59.4M -48.91%
EPS (Diluted) $-1.22

Balance Sheet Metrics

Total Assets 596.7M
Total Liabilities 543.5M
Shareholders Equity 53.2M
Debt to Equity 10.21

Cash Flow Metrics

Operating Cash Flow -40.2M
Free Cash Flow -43.7M

Revenue & Profitability Trend

Axsome Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 385.7M 270.6M 50.0M 0 0
Cost of Goods Sold i 33.3M 26.1M 5.2M 0 0
Gross Profit i 352.4M 244.5M 44.8M 0 0
Gross Margin % i 91.4% 90.4% 89.6% 0.0% 0.0%
Operating Expenses
Research & Development i 187.1M 97.9M 57.9M 58.1M 70.2M
Selling, General & Administrative i 411.4M 323.1M 159.3M 66.6M 28.9M
Other Operating Expenses i - - - - -
Total Operating Expenses i 598.4M 421.1M 217.2M 124.7M 99.1M
Operating Income i -252.4M -182.9M -176.5M -124.7M -99.1M
Operating Margin % i -65.5% -67.6% -352.7% 0.0% 0.0%
Non-Operating Items
Interest Income i - - - - -
Interest Expense i 6.6M 6.5M 7.3M 5.7M 2.6M
Other Non-Operating Income -28.1M -48.9M -3.3M - -1.2M
Pre-tax Income i -287.1M -238.3M -187.1M -130.4M -102.9M
Income Tax i 85.0K 960.0K 0 0 -
Effective Tax Rate % i 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income i -287.2M -239.2M -187.1M -130.4M -102.9M
Net Margin % i -74.5% -88.4% -374.0% 0.0% 0.0%
Key Metrics
EBITDA i -244.5M -176.1M -172.1M -124.6M -99.0M
EPS (Basic) i $-5.99 $-5.27 $-4.60 $-3.47 $-2.77
EPS (Diluted) i $-5.99 $-5.27 $-4.60 $-3.47 $-2.77
Basic Shares Outstanding i 47914253 45425212 40655941 37618599 37206928
Diluted Shares Outstanding i 47914253 45425212 40655941 37618599 37206928

Income Statement Trend

Axsome Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 315.4M 386.2M 200.8M 86.5M 183.9M
Short-term Investments i - - - - -
Accounts Receivable i 142.0M 94.8M 37.7M 0 -
Inventory i 15.7M 15.1M 4.3M 0 -
Other Current Assets 12.0M 8.1M 2.8M 45.3K 148.4K
Total Current Assets i 485.1M 504.3M 245.6M 86.5M 184.0M
Non-Current Assets
Property, Plant & Equipment i 584.0K 846.0K 722.0K 283.8K 52.6K
Goodwill i 71.0M 77.4M 80.3M 0 -
Intangible Assets i 46.9M 53.3M 59.7M - -
Long-term Investments - - - - -
Other Non-Current Assets 18.5M 11.0M 14.7M 322.9K 317.4K
Total Non-Current Assets i 83.4M 84.0M 85.8M 1.3M 2.1M
Total Assets i 568.5M 588.2M 331.5M 87.8M 186.1M
Liabilities
Current Liabilities
Accounts Payable i 72.0M 40.7M 38.6M 13.1M 13.5M
Short-term Debt i 3.3M 1.3M 425.0K 620.7K 1.2M
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 8.3M 6.4M 5.9M - -
Total Current Liabilities i 230.1M 138.9M 96.6M 23.1M 23.4M
Non-Current Liabilities
Long-term Debt i 189.7M 185.1M 94.3M 49.1M 48.9M
Deferred Tax Liabilities i - - - - -
Other Non-Current Liabilities 91.7M 73.3M 31.1M - -
Total Non-Current Liabilities i 281.4M 258.4M 125.4M 49.1M 48.9M
Total Liabilities i 511.5M 397.3M 221.9M 72.2M 72.3M
Equity
Common Stock i 5.0K 5.0K 4.0K 3.8K 3.7K
Retained Earnings i -1.1B -835.6M -596.3M -409.2M -278.8M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 57.0M 191.0M 109.6M 15.6M 113.8M
Key Metrics
Total Debt i 193.0M 186.4M 94.7M 49.7M 50.1M
Working Capital i 255.0M 365.4M 149.1M 63.5M 160.6M

Balance Sheet Composition

Axsome Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -287.2M -239.2M -187.1M -130.4M -102.9M
Depreciation & Amortization i 8.0M 6.8M 4.4M 76.0K 77.7K
Stock-Based Compensation i 85.2M 62.6M 37.7M 20.8M 14.8M
Working Capital Changes i -18.3M -59.5M -17.5M -366.5K 2.0M
Operating Cash Flow i -180.6M -176.2M -157.7M -108.9M -78.1M
Investing Activities
Capital Expenditures i -270.0K -582.0K -702.0K -308.0K -45.9K
Acquisitions i 0 0 -53.0M 0 0
Investment Purchases i - - - - -
Investment Sales i - - - - -
Investing Cash Flow i -270.0K -582.0K -53.7M -308.0K -45.9K
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i 0 85.0M 45.0M 0 50.0M
Debt Repayment i -990.0K - 0 0 -21.7M
Financing Cash Flow i 27.2M 318.6M 278.3M 6.7M 41.4M
Free Cash Flow i -128.7M -145.7M -117.2M -108.5M -78.5M
Net Change in Cash i -153.7M 141.8M 66.9M -102.5M -36.8M

Cash Flow Trend

Axsome Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) -19.92
Forward P/E -54.93
Price to Book 80.87
Price to Sales 12.09
PEG Ratio 0.48

Profitability Ratios

Profit Margin -49.88%
Operating Margin -29.87%
Return on Equity -280.69%
Return on Assets -21.90%

Financial Health

Current Ratio 1.57
Debt to Equity 297.38
Beta 0.51

Per Share Data

EPS (TTM) $-5.07
Book Value per Share $1.47
Revenue per Share $10.15

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
axsm 5.9B -19.92 80.87 -280.69% -49.88% 297.38
Vertex 108.0B 29.16 6.12 22.77% 31.86% 8.89
Alnylam 60.2B -209.88 240.24 -257.83% -12.96% 1,093.31
Madrigal 9.9B -19.95 13.93 -36.30% -54.68% 17.81
Bio-Techne 9.8B 136.85 5.08 3.68% 6.02% 23.14
Corcept Therapeutics 9.5B 80.64 14.96 21.70% 18.67% 1.04

Financial data is updated regularly. All figures are in the company's reporting currency.